The Experts below are selected from a list of 15444 Experts worldwide ranked by ideXlab platform

Claessens Frank - One of the best experts on this subject based on the ideXlab platform.

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    Elsevier, 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.status: publishe

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    'Elsevier BV', 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.publisher: Elsevier articletitle: A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton journaltitle: Molecular and Cellular Endocrinology articlelink: http://dx.doi.org/10.1016/j.mce.2017.05.012 content_type: article copyright: © 2017 Elsevier B.V. All rights reserved.status: publishe

Thul Matthias - One of the best experts on this subject based on the ideXlab platform.

  • How Much Is the Gap? Efficient Jump Risk-Adjusted Valuation of Leveraged Certificates
    'Informa UK Limited', 2017
    Co-Authors: Zhang, Ally Quan, Thul Matthias
    Abstract:

    This paper develops a novel and highly efficient numerical algorithm for the gap risk-adjusted valuation of leveraged certificates. The existing literature relies on Monte Carlo simulations, which are not fast enough to be used in a market making environment. This is because issuers need to compute thousands of price updates per second. By valuing leveraged certificates as multi-window barrier options, we explicitly model random jumps that occur at known times, such as between the exchange closing and re-opening. Our algorithm combines the one-day transition probability with Simpson's numerical integration rule. This yields a backward Induction Scheme which requires a significantly coarser spacial and time grid than finite difference methods. We confirm its robustness and accuracy through Monte Carlo simulations

  • How Much is the Gap?:Efficient Overnight Jump Risk-Adjusted Valuation of Leveraged Certificates
    'Informa UK Limited', 2017
    Co-Authors: Zhang Quan, Thul Matthias
    Abstract:

    This paper develops a novel and highly efficient numerical algorithm for the gap risk-adjusted valuation of leveraged certificates. The existing literature relies on Monte Carlo simulations, which are not fast enough to be used in a market making environment. This is because issuers need to compute thousands of price updates per second. By valuing leveraged certificates as multi-window barrier options, we explicitly model random jumps that occur at known times, such as between the exchange closing and re-opening. Our algorithm combines the one-day transition probability with Simpson’s numerical integration rule. This yields a backward Induction Scheme which requires a significantly coarser spatial and time grid than finite difference methods. We confirm its robustness and accuracy through Monte Carlo simulations

Jardi Ferran - One of the best experts on this subject based on the ideXlab platform.

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    Elsevier, 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.status: publishe

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    'Elsevier BV', 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.publisher: Elsevier articletitle: A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton journaltitle: Molecular and Cellular Endocrinology articlelink: http://dx.doi.org/10.1016/j.mce.2017.05.012 content_type: article copyright: © 2017 Elsevier B.V. All rights reserved.status: publishe

Schollaert Dieter - One of the best experts on this subject based on the ideXlab platform.

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    Elsevier, 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.status: publishe

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    'Elsevier BV', 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.publisher: Elsevier articletitle: A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton journaltitle: Molecular and Cellular Endocrinology articlelink: http://dx.doi.org/10.1016/j.mce.2017.05.012 content_type: article copyright: © 2017 Elsevier B.V. All rights reserved.status: publishe

Van Den Bosch Ludo - One of the best experts on this subject based on the ideXlab platform.

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    Elsevier, 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.status: publishe

  • A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton
    'Elsevier BV', 2017
    Co-Authors: Jardi Ferran, Laurent Michaël, Dubois Vanessa, Khalil Rougin, Deboel Ludo, Schollaert Dieter, Van Den Bosch Ludo, Decallonne Brigitte, Carmeliet Geert, Claessens Frank
    Abstract:

    The selective estrogen receptor modulator tamoxifen exerts estrogen agonistic or antagonistic actions on several tissues, including bone. The off-target effects of tamoxifen are one of the most widely recognized pitfalls of tamoxifen-inducible Cre recombinases (CreERs), potentially confounding the phenotypic findings. Still, the validation of tamoxifen Induction Schemes that minimize the side effects of the drug has not been addressed. Here, we compared the side effects on the skeleton and other androgen-responsive targets of a shortened tamoxifen regimen (2 doses of 190 mg/kg body weight by oral gavage) to a standard protocol (4 doses) and determined their efficiency in inducing CreER-mediated gene deletion. In addition, both a vehicle- and a 10-dose group, which served as a positive control for tamoxifen side effects, were also included. For this purpose, we generated male mice with a floxed androgen receptor (AR) and a neuron-specifically expressed CreER. Treatment with two doses of tamoxifen was the only regimen that did not diminish androgenic bioactivity, as assessed by both seminal vesicles and levator ani/bulbocavernosus muscle weights and serum testosterone concentrations. Similarly, trabecular and cortical femoral bone structure were dramatically altered by both the standard and high-dose protocols but not by the shortened version. Serum osteocalcin and bone-gene expression analyses confirmed the absence of effects on bone by 2 doses of tamoxifen. This protocol decreased AR mRNA levels efficiently and specifically in the nervous system. Thus, we optimized a protocol for tamoxifen-induced CreER gene deletion in mice without off-target effects on bone and male reproductive organs.publisher: Elsevier articletitle: A shortened tamoxifen Induction Scheme to induce CreER recombinase without side effects on the male mouse skeleton journaltitle: Molecular and Cellular Endocrinology articlelink: http://dx.doi.org/10.1016/j.mce.2017.05.012 content_type: article copyright: © 2017 Elsevier B.V. All rights reserved.status: publishe